COMPANY PROFILE

Kardigan

Explore full profile

Heart health company aiming to make cardiovascular disease preventable and curable with innovative drug development

West Windsor Township, United StatesFounded 2023Biotech & Life Sciences

Valuation $500M–1B Last recorded · 2026

Headcount 100–500 Current team size

Total funding $500M–1B Disclosed equity funding

Unlock exact values

About Kardigan

Kardigan is a heart health company dedicated to transforming the landscape of cardiovascular medicine. With a leadership team of seasoned biopharma veterans, the company focuses on making cardiovascular disease preventable and curable. Kardigan operates in the biotechnology sector, targeting patients with cardiovascular conditions. The business model revolves around the discovery and development of multiple important medicines at an unprecedented pace, leveraging their deep expertise in cardiovascular drug development. Kardigan's revenue is generated through the commercialization of these medicines, aiming to address the global challenge of cardiovascular disease, which remains a leading cause of death worldwide. The company is driven by a commitment to modernize the discovery and development process, bringing a high level of focus and passion to their mission.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2023
Headquarters: West Windsor Township, United States
Employees: 176
Open positions: 7
Dealroom signal: 93.8/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Verified Unicorns and $1B Exits, Biotech and Pharma, Woman Founder, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Investment activity: 1 company, latest Mar 2025
Capital deployed: —
Preferred round: ACQUISITION
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
IPOOther financing	Jun 2026	$400M	$1.5B	Undisclosed	↗
SERIES BOther financing	Oct 2025	$254M	$1B	Fidelity Investments · ARCH Venture Partners · T. Rowe Price · Sequoia Heritage	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Growth	Margin
2026	—	—
2025	—	—
2024	—	—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Kardigan website traffic

Latest recorded traffic for Kardigan is 12K monthly website visits, up 100% over the last three months. Kardigan's team grew 193.3% over the past year.

Latest monthly visits12K 3-month web change+100% 1-year team growth+193.3%

Monthly website visitsFeb 2025–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

8 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
FBFirefly BioUnlocking new classes of payloads to maximize the potential of ADCs	South San Francisco, United States	Acquired	24	$94M	$1B
OTOrna TherapeuticsOrna Therapeutics - Ahead of the Curve	Cambridge, United States	Acquired
SBSana BiotechnologyFocused on creating and delivering engineered cells as medicines for patients	Seattle, United States	Operational
MEMeiraGTxClinical-stage genetic medicine using regulatable riboswitch technology	London, United Kingdom	Operational
BIBioNTechDevelops personalized immunotherapies with a focus on cancer medicine	Mainz, Germany	Operational
OTOrchard TherapeuticsHematopoietic stem cell gene therapies for rare diseases	London, United Kingdom	Acquired
CPCardior PharmaceuticalsNon-coding RNA-based therapeutics in heart failure	Hanover, Germany	Acquired
SASansanimaHuman cell-based assays replacing animal testing.	Sheffield, United Kingdom	Operational